0001104659-16-130180.txt : 20160629 0001104659-16-130180.hdr.sgml : 20160629 20160629185305 ACCESSION NUMBER: 0001104659-16-130180 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160629 FILED AS OF DATE: 20160629 DATE AS OF CHANGE: 20160629 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 ARSENAL STREET STREET 2: SUITE 130 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 480 ARSENAL STREET STREET 2: SUITE 130 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simonian Nancy A CENTRAL INDEX KEY: 0001359574 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 161740020 MAIL ADDRESS: STREET 1: C/O ARQULE, INC. STREET 2: 19 PRESIDENTIAL WAY CITY: WOBURN STATE: MA ZIP: 01801 3 1 a3.xml 3 X0206 3 2016-06-29 0 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001359574 Simonian Nancy A C/O SYROS PHARMACEUTICALS, INC. 620 MEMORIAL DRIVE, SUITE 300 CAMBRIDGE MA 02139 1 1 1 0 President & CEO Common Stock 304036 D Common Stock 80000 I By the Douglas and Nancy Cole Family Trust f/b/o Bennett H. Cole Common Stock 80000 I By the Douglas and Nancy Cole Family Trust f/b/o William H. Cole Employee Stock Option (right to buy) 1.01 2023-05-22 Common Stock 23454 D Employee Stock Option (right to buy) 1.01 2023-05-22 Common Stock 75050 D Employee Stock Option (right to buy) 3.04 2024-10-22 Common Stock 12083 D Employee Stock Option (right to buy) 3.04 2025-02-05 Common Stock 71094 D Employee Stock Option (right to buy) 3.04 2025-06-09 Common Stock 43048 D Employee Stock Option (right to buy) 3.04 2025-06-09 Common Stock 43047 D Employee Stock Option (right to buy) 8.51 2026-03-31 Common Stock 93333 D Series A-2 Preferred Stock Common Stock 66666 D Option vested as to 25% of the shares on July 2, 2013 with the remaining shares vesting in equal monthly installments thereafter through July 2, 2016. Option vests upon the achievement of performance-based criteria, and in any event will vest in full on July 2, 2018. Option vested as to 25% of the shares on September 29, 2015 with the remaining shares vesting in equal monthly installments thereafter through September 29, 2018. Option vested as to 25% of the shares on February 5, 2016 with the remaining shares vesting in equal monthly installments thereafter through February 5, 2019. Option vests as to 25% of the shares on June 9, 2016 with the remaining shares vesting in equal monthly installments thereafter through June 9, 2019. Option vests upon the achievement of performance-based criteria, and in any event will vest in full on June 9, 2021. Option vests as to 25% of the shares on March 31, 2017 with the remaining shares vesting in equal monthly installments thereafter through March 31, 2020. The Series A-2 Preferred Stock is convertible into Common Stock on a 3.75for-one basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Exhibit List Exhibit 24 - Power of Attorney /s/ Jorge Conde, attorney-in-fact 2016-06-29 EX-24 2 ex-24.htm EX-24

Exhibit 24

 

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

 

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Nancy Simonian, Kyle Kuvalanka and Jorge Conde, signing singly and each acting individually, as the undersigned’s true and lawful attorney-in-fact with full power and authority as hereinafter described to:

 

(1)           execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Syros Pharmaceuticals, Inc. (the “Company”), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the “Exchange Act”);

 

(2)           do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the “SEC”) and any stock exchange or similar authority, including without limitation the filing of a Form ID or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;

 

(3)           seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information regarding transactions in the Company’s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and

 

(4)           take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act.  The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned’s responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 26th day of June, 2016.

 

 

 

/s/ Nancy Simonian

 

Signature

 

 

 

 

 

Nancy Simonian

 

Print Name